Scarica l'app Stockscreener
14.53
0.41%
0.06
Dopo l'orario di chiusura:
14.65
0.12
+0.83%
Precedente Chiudi:
$14.47
Aprire:
$14.48
Volume 24 ore:
2.89M
Relative Volume:
1.91
Capitalizzazione di mercato:
$1.43B
Reddito:
-
Utile/perdita netta:
$-44.84M
Rapporto P/E:
-30.91
EPS:
-0.47
Flusso di cassa netto:
$-44.23M
1 W Prestazione:
-16.97%
1M Prestazione:
-17.26%
6M Prestazione:
+20.88%
1 anno Prestazione:
+7.31%
Intervallo 1D:
$14.26
$14.91
Intervallo di 1 settimana:
$14.26
$17.54
Portata 52W:
$10.01
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Confronta SPRY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
14.53 | 1.43B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
Will ARS Pharmaceuticals Inc. Benefit From Sector TailwindsMarket Risk Analysis & Stepwise Trade Signal Implementation - newsyoung.net
ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway - simplywall.st
ARS Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates - MSN
ARS Pharmaceuticals Plunges 9.23%—What's Unraveling in the Lab? - AInvest
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q2 2025 Earnings Call Transcript - Insider Monkey
ARS Pharmaceuticals stock maintains Strong Buy rating at Raymond James on strong neffy sales - Investing.com India
ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets - MSN
ARS Pharmaceuticals Reports Strong Growth for neffy - TipRanks
ARS Pharmaceuticals 2025 Q2 Earnings Sharp Revenue Surge Amid Widening Losses - AInvest
ARS Pharmaceuticals shares rise 1.07% after-hours after reporting Q2 revenue of $15.7 million and global expansion of neffy. - AInvest
ARS Pharma Sales Jump 3,040% in Q2 - The Motley Fool
ARS Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
ARS Pharmaceuticals' Q2 2025: Navigating Key Contradictions in DTC Impact, Inventory, and NUCLEUS Commercialization - AInvest
ARS Pharmaceuticals reports reports Q2 EPS (46c), consensus (51c) - TipRanks
SPRY Plummets 11.5%: What's Behind the Sharp Decline? - AInvest
Transcript : ARS Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
ARS Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: ARS Pharmaceuticals Q2 2025 revenue beats forecast - Investing.com
ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises - MarketScreener
ARS Pharmaceuticals earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
ARS Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
ARS Pharmaceuticals, Inc. SEC 10-Q Report - TradingView
Earnings Flash (SPRY) ARS Pharmaceuticals, Inc. Reports Q2 Revenue $15.7M, vs. FactSet Est of $13.8M - MarketScreener
ARS Pharmaceuticals Reports Second Quarter 2025 Financial - GlobeNewswire
ARS Pharmaceuticals Posts $15.7 Million Q2 Revenue, Neffy Sales Reach $12.8 Million in US. - AInvest
ARS Pharma (SPRY) 8-K: Q2 Results & Updated Investor Presentation Filed | SPRY SEC FilingForm 8-K - Stock Titan
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) - Yahoo Finance
TR | OpenAI4o Maintains ARS Pharmaceuticals(SPRY.US) With Hold Rating, Cuts Target Price to $16.5 - 富途牛牛
What drives ARS Pharmaceuticals Inc.’s stock priceShort-Term Explosive Growth - 선데이타임즈
What ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) 26% Share Price Gain Is Not Telling You - 富途牛牛
ARS Pharmaceuticals Inc expected to post a loss of 47 cents a shareEarnings Preview - TradingView
ARS Pharmaceuticals SPRY 2025Q2 Earnings Preview Upside Potential Amid Strategic Developments - AInvest
What are the risks of holding ARS Pharmaceuticals Inc.Maximum Return Portfolio Ideas - thegnnews.com
ARS Pharmaceuticals: Pioneering a Needle-Free Revolution in Allergy Treatment - AInvest
ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results - GlobeNewswire
ARS Pharmaceuticals to discuss Q2 2025 financial results Aug 13. - AInvest
ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results - Stock Titan
What drives ARS Pharmaceuticals Inc. stock priceCapitalize on emerging trends for profits - Jammu Links News
How volatile is ARS Pharmaceuticals Inc. stock compared to the marketBuild a portfolio that outperforms the market - Jammu Links News
How does ARS Pharmaceuticals Inc. compare to its industry peersAchieve breakthrough financial results today - Jammu Links News
What institutional investors are buying ARS Pharmaceuticals Inc. stockMarket-beating returns - Jammu Links News
Is ARS Pharmaceuticals Inc. a growth stock or a value stockMassive portfolio appreciation - Jammu Links News
What analysts say about ARS Pharmaceuticals Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
Is ARS Pharmaceuticals Inc. stock overvalued or undervaluedBuild a portfolio that grows with the market - Jammu Links News
What makes ARS Pharmaceuticals Inc. stock price move sharplyHigh-profit capital plays - Jammu Links News
How does ARS Pharmaceuticals Inc. generate profit in a changing economyMarket-crushing stock picks - Jammu Links News
How strong is ARS Pharmaceuticals Inc. company’s balance sheetTriple-digit profit margins - Jammu Links News
Does ARS Pharmaceuticals Inc. stock perform well during market downturnsStay ahead with advanced stock screening tools - Jammu Links News
What is the risk reward ratio of investing in ARS Pharmaceuticals Inc. stockGet expert alerts on market-moving stocks - Jammu Links News
ARS Pharmaceuticals Inc. Stages Intraday Comeback — Trend ChangeConservative Long Term Growth Plans Under Review - beatles.ru
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.41%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):